Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $8.00

Sana Biotechnology (NASDAQ:SANA) had its price objective boosted by Citizens Jmp from $5.00 to $8.00 in a research note issued to investors on Thursday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

A number of other research analysts also recently weighed in on SANA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Morgan Stanley initiated coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price for the company. Citigroup reaffirmed an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday. Finally, Wedbush started coverage on shares of Sana Biotechnology in a research report on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 price objective for the company. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Sana Biotechnology Trading Up 1.0%

Sana Biotechnology stock opened at $4.95 on Thursday. The company has a market cap of $1.18 billion, a P/E ratio of -4.67 and a beta of 1.91. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.30. The company has a fifty day simple moving average of $3.96 and a 200 day simple moving average of $3.27.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. On average, equities research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SANA. Baillie Gifford & Co. boosted its holdings in shares of Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after buying an additional 1,371,775 shares during the period. Marex Group plc bought a new stake in shares of Sana Biotechnology during the 2nd quarter worth about $10,423,000. AQR Capital Management LLC boosted its holdings in shares of Sana Biotechnology by 136.7% during the 2nd quarter. AQR Capital Management LLC now owns 1,356,363 shares of the company’s stock worth $3,703,000 after buying an additional 783,217 shares during the period. Corient Private Wealth LLC boosted its holdings in shares of Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock worth $3,101,000 after buying an additional 824,505 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Sana Biotechnology by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,066,304 shares of the company’s stock worth $1,791,000 after buying an additional 9,792 shares during the period. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.